Nature

Complement in cancer: untangling an intricate relationship

Complement potentiates various forms of cancer therapy, including antibody-mediated cytotoxicity, vaccines and radiotherapy. Complement-dependent cytotoxicity can be improved by optimizing antibody ...
Business Wire

Alnylam Reports Positive Initial Clinical Results for ALN-CC5, an Investigational RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated ...

– In Ongoing Phase 1/2 Study, Single Subcutaneous Doses of ALN-CC5 Achieve Potent, Statistically Significant, and Highly Durable C5 Knockdown of up to 96% – – After Single Dose, ALN-CC5 Also Achieves ...
Seeking Alpha

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

-- Poster presentation to highlight data from completed first-in-human, Phase 1 ascending dose clinical trial of ADX-097 in healthy volunteers; results support Phase 2 dose selection and continued ...
Business Wire

Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Patients with Paroxysmal Nocturnal ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that the pivotal Phase 3 study of ALXN1210, the Company’s investigational long-acting C5 complement ...
manilatimes

ADARx Pharmaceuticals Announces Positive Interim Phase 1 Clinical Data for its Novel siRNA Targeting Complement Factor B (CFB)

- Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB silencing - - Phase 2 studies are ongoing to assess the ...